ADVERTISEMENT

Strides Pharma Science Ltd

BSE - 532531
NSE - STAR
ISIN - INE939A01011

Companies
Strides Pharma gets USFDA approval for generic Ibuprofen oral suspension
The product will be manufactured at the firm's facility in Bengaluru and will be marketed by Strides Pharma Inc in the US market
Companies
Strides Pharma unit gets USFDA for generic product
The product will be manufactured at the company's facility at Bengaluru
Companies
Strides third-quarter revenues marginally up by 8 percent even as losses continue to mount
Net loss widens to ₹87 crore
Technical Analysis
What is the long-term outlook for IEX and Navin Fluorine stocks?
Todays Pick
Strides Pharma Science (₹542.7): Sell
Companies
Strides Pharma to acquire arms of Endo in the US for $24 mn
The cumulative addressable market for the acquired portfolio was $4.7 billion as of May 2021
Companies
Strides Pharma partners with Nasdaq listed TLC to launch Liposomal Amphotericin B
The company on Thursday, announced that the CDSCO in India has approved TLC’s New Drug Application
Companies
Strides Pharma Science posts ₹43.74 cr Q4 profits
The company’s total income for Q4 is up 44.83 per cent for Q4 at ₹921.54 crore
Companies
Strides Pharma arm raises $195 million through series B, C funding
Companies
Strides gets USFDA nod for potassium chloride for oral solution
Companies
Strides gets USFDA nod for Potassium Chloride for Oral Solution
Used for prevention, treatment of low blood levels of potassium
Science
Strides gets USFDA nod for Ibuprofen OTC oral suspension
Strides is focusing on building a private label business in the US by leveraging its portfolio of products across soft gels, tablets, capsules, topicals, powders and oral solutions

ADVERTISEMENT

ADVERTISEMENT